Sydnexis
We focus on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic.
We focus on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic.
Sydnexis is a pharmaceutical startup founded in 2014 with the mission to combat the increasing prevalence of myopia among children. The company's focus is on developing a proprietary, stable, low-dose atropine eyedrop to treat myopia progression and reduce the risk of ocular co-morbidities. With the recent $45.00M Series B investment secured on 10 August 2021, Sydnexis has garnered the support of prominent investors including Longitude Capital, RA Capital Management, Bluestem Capital, Visionary Ventures, Medicxi, and SC Master Fund.
Myopia's surge in prevalence over the last 30 years has heightened concerns about its associated ophthalmic co-morbidities. Sydnexis recognizes the urgency of addressing the juvenile-onset myopia pandemic and emphasizes the importance of Formulation Matters! in creating a best-in-class low-dose atropine formulation. As it operates in the Manufacturing and Pharmaceutical industries, Sydnexis stands at the forefront of innovating solutions to combat childhood myopia, paving the way for a healthier vision for future generations.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $45.00M | 6 |
|
10 Aug 2021 |
| Venture Round | $5.50M | 2 |
|
06 Oct 2017 |
No recent news or press coverage available for Sydnexis.
We care about your data, and we'd love to use cookies make your experience better.
